



Montana Healthcare Programs
Drug Prior Authorization Coverage Criteria

Mavenclad™ (cladribine)

Review Criteria

Member must meet all the following criteria:

- Subject to Preferred Drug List
- Member must be 18 years of age or older
- Must be written by or in consultation with a neurologist
 - If not written by or in consultation with a neurologist, copy of recent consult must be submitted
- Member must have diagnosis of either relapsing-remitting or secondary progressive disease - **THIS IS NOT INDICATED FOR CIS**

Limitations:

- QL: 2 cycles per treatment course and may be renewed one time only after at least 43 weeks (total of 2 treatment courses or 4 cycles in 2 year period)
 - Initial (first course): 100 mg per cycle (2 cycles only); 2 blister cards
 - Renewal (second course - 1 time only): 100 mg per cycle (2 cycles only); total 2 blister cards